Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.72 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800073 | 0.85 | TUBB4A (0.60) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL31696789 | 0.85 | TUBB4A (0.60) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL184025 | 0.84 | TSHR (0.70) | CYP1A2POLBALDH1A1GAAHPGD | |
| SCHEMBL29521706 | 0.84 | TSHR (0.70) | CYP1A2POLBALDH1A1GAAHPGD | |
| SCHEMBL15814046 | 0.84 | SLC22A6 (1.00) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL15289000 | 0.84 | MEN1 (1.00) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL29532454 | 0.84 | MEN1 (1.00) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| Vanillic Acid SCHEMBL26179 | 0.82 | HTT (1.00) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| Vanillic Acid SCHEMBL9711598 | 0.82 | HTT (1.00) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| Apocynin SCHEMBL109514 | 0.82 | MEN1 (0.75) | MEN1KMT2ASLC22A6SLC22A8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024073011-A1 | TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024073013-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| EP-2835634-B1 | Methods and devices for calibrating the mobility axis of an ion mobility spectrum | BRUKER DALTONIK GMBH (DE) | 2017-10-04 | — | — | EP | claimed |
| EP-3109226-A1 | PROCESS FOR PREPARING VANILLIN | BASF SE (DE) | 2016-12-28 | — | — | EP | claimed |
| US-9153423-B2 | Methods and devices for calibrating the mobility axis of an ion mobility spectrum | BRUKER OPTICS GMBH & CO. KG (DE) | 2015-10-06 | — | — | US | claimed |
| US-20150129760-A1 | METHODS AND DEVICES FOR CALIBRATING THE MOBILITY AXIS OF AN ION MOBILITY SPECTRUM | BRUKER OPTICS GMBH & CO. KG (DE) | 2015-05-14 | — | — | US | claimed |
| EP-2835634-A1 | Methods and devices for calibrating the mobility axis of an ion mobility spectrum | Bruker Daltonik GmbH (DE) | 2015-02-11 | — | — | EP | claimed |
| EP-2670501-A1 | REMOVING COMPOUNDS FROM WINE | Constellation Brands U.S. Operations, Inc. (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2012106265-A1 | REMOVING COMPOUNDS FROM WINE | CONSTELLATION WINES U.S., INC. (US) | 2012-08-09 | — | — | WO | claimed |
| US-20120196024-A1 | REMOVING COMPOUNDS FROM WINE | CONSTELLATION WINES U.S., INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-3951914-A | Process for preparing poly(1,4-benzamide) in cyclic sulfone media | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-20 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240300930-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-09-12 | — | — | US | disclosed |
| US-3991016-A | Poly(1,4-benzamide) copolymers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-09 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
| US-3951914-A | Process for preparing poly(1,4-benzamide) in cyclic sulfone media | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300930-A1 | NOVEL PROCESS FOR THE PREPARATION OF 2,5-DICHLORO-3-(5-(3,4-DIHYDROXY-5-NITROPHENYL)-1,2,4-OXADIAZOL-3-YL)-4,6-DIMETHYLPYRIDINE-1-OXIDE | NOX4, DDT, QDPR | MEN1 2741/4885KMT2A 1854/4885SLC22A6 4495/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MEN1 4053/4885KMT2A 1308/4885SLC22A6 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.